Post-translational modifications in bladder cancer: Expanding the tumor target repertoire.

Oo, Htoo Zarni; Seiler, Roland; Black, Peter C; Daugaard, Mads (2018). Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. Urologic oncology - seminars and original investigations, 38(12), pp. 858-866. Elsevier 10.1016/j.urolonc.2018.09.001

[img] Text
Se_Post-translational modifications in bladder cancer, Expanding the tumor target repertoire.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (625kB) | Request a copy

Over the past decade, genomic and transcriptomic analyses have uncovered promising tumor antigens including immunotherapeutic targets in bladder cancer (BCa). Conventional tumor antigens are proteins expressed on the plasma membrane of tumor cells such as EGFR, FGFR3, and ERBB2 in BCa, which can be targeted by antibodies or similar epitope-specific binding reagents. The cellular proteome consists of ∼100,000 proteins but the expression of these proteins is rarely unique to tumor cells. Many tumor-associated proteins are post-translationally modified with phosphorylation, glycosylation, ubiquitination, or SUMOylation moieties. Although these modifications expand the complexity, they potentially offer novel targeting opportunities across tumor sub-populations. Experimental targeting of cancer-specific post-translational modifications (PTMs) has shown encouraging results in pre-clinical models of BCa, which could potentially overcome issues with inherent intra-tumor heterogeneity due to simultaneous expression on different proteins. Here, we review current knowledge on post-translational modifications in BCa and highlight recent efforts in experimental targeting strategies.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Seiler-Blarer, Roland

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1078-1439

Publisher:

Elsevier

Language:

English

Submitter:

Jeannine Wiemann

Date Deposited:

05 Nov 2018 14:54

Last Modified:

02 Mar 2023 23:31

Publisher DOI:

10.1016/j.urolonc.2018.09.001

PubMed ID:

30342880

Uncontrolled Keywords:

Bladder cancer Post-translational modification (PTM) Secondary modification Targeted therapy

BORIS DOI:

10.7892/boris.120924

URI:

https://boris.unibe.ch/id/eprint/120924

Actions (login required)

Edit item Edit item
Provide Feedback